Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 36

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 36
---
 of P. aeruginosain the sputum measured at several timepoints suggest improvement
in bacterial load reduction for subjects treated with AP-PA02 at the end of treatment as compared to placebo after ten days of dosing.
In addition, a correlation was seen between increasing phage dose (higher AP-PA02 exposures) and reduction in the bacterial load, supporting
the biologic plausibility of a bacterial specific mechanism of action and creating the opportunity for phage as a therapeutic alternative
to inhaled antibiotics. This study was supported by the Cystic Fibrosis Foundation (the “CFF”), which granted us a Therapeutics
Development Award of $5.0 million. We received the full award’s amount, including the final payment of $0.3 million, in January 2024.
Following the promising Phase 1b/2a results of favorable safety and tolerability profile and plausible mechanism of action, an additional
confirmatory Phase 2 trial was initiated in non-cystic fibrosis bronchiectasis (“NCFB”) patients with similar chronic pulmonary
disease with infections due to P. aeruginosa.

<div align='center'>2</div>

Clinical Development of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis: Completed Phase 2 Study

On
February 22, 2022, Armata announced that it had received from the FDA the approval to proceed for our IND application for AP-PA02,
in a second indication, NCFB. On December 19, 2024, Armata announced encouraging results from the completed “Tailwind”
study – a Phase 2 multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety, phage kinetics, and efficacy
of inhaled AP-PA02 in subjects with NCFB and chronic pulmonary P. aeruginosa infection. Data indicated that inhaled AP-PA02
provides a durable reduction of P. aeruginosa in the lung, with a favorable safety and tolerability profile. The Tailwind study
was conducted in two cohorts running in parallel: subjects in one cohort (cohort A) received inhaled AP-PA02 as monotherapy, while subjects
in another cohort (cohort B) received inhaled AP-PA02 in combination with inhaled anti-pseudomonal antibiotic treatment. Subjects in both
cohorts were dosed at home by nebulization with study drug administered every 12 hours for 10 days and were